Decimal assay for additivity of drugs permits delineation of synergy and antagonism.
Although there are many in vitro tests for drug interactions, few possess a linear, predictable dose-dependent end point or have a precise definition for additivity. Therefore, a new test with both of these features, the decimal assay for additivity, was developed. This test is based on a disk diffusion assay and the strict linear relationship between drug mass and size of the inhibition zone. When the decimal assay for additivity was applied to combinations known on a mechanistic basis to be additive, synergistic, or antagonistic, results of the new test always reflected the expected drug interaction. For example, synergy between trimethoprim and sulfamethoxazole was detected in tests with Escherichia coli and Haemophilus influenzae, as was antagonism between cefoxitin and cefotaxime in tests with Enterobacter cloacae. Quinolones plus chloramphenicol appeared to be antagonistic. In addition to correctly identifying the drug interaction, the decimal assay for additivity identified the drug ratio producing the maximal drug interaction. These results suggest that the decimal assay for additivity should prove very useful in future studies of drug interactions.
Sanders
C C
CC
Department of Medical Microbiology, Creighton University School of Medicine, Omaha, Nebraska 68178.
Sanders
W E
WE
Moland
E S
ES
D042462:4-Quinolones; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects; D004058:Diffusion; D004336:Drug Antagonism; D004357:Drug Synergism; D008826:Microbial Sensitivity Tests / Q000379:methods*; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology
D042462:4-Quinolones; D000900:Anti-Bacterial Agents; D011500:Protein Synthesis Inhibitors